Use Instructions

35
Adding New Class of Heart Failure Drugs
Table 13 shows the data reported in Appendix Table 12, Subjects Adding New Class
of Heart Failure Drugs by Six Months in Cohort D Control (n=125). in the JACC 2020
article supplementary material.
During the 6-month follow-up there was a significant difference in medical
management between the 2 arms, with a higher number of medications added in
the control group (Supplemental Table 12, Zile et al).1 Patients in the control
group were more likely to have a new class of drugs added compared to BAT, with
BAT still providing benefit and meeting the endpoints for 6MHW, QoL, and NT-
proBNP.
Table 13: Addition of New Class of Heart Failure Drugs
4
in Intended Use Subjects
Control
(N=125)
BAT (N=120)
Difference
(95% CI)
P-value *
Any Medication Class
36 (28.8%)
21 (17.5%)
11.3% (0.8,
21.8)
0.049
ACE / ARB
5 (4.0%)
4 (3.3%)
0.7% (-4.0, 5.4)
1.000
ARNI (Sacubitril/Valsartan)
20 (16.0%)
5 (4.2%)
11.8% (4.5,
19.2)
0.003
Beta Blocker
4 (3.2%)
3 (2.5%)
0.7% (-3.5, 4.9)
1.000
Digitalis
3 (2.4%)
0 (0.0%)
2.4% (-0.3, 5.1)
0.247
Diuretic
3 (2.4%)
5 (4.2%)
-1.8% (-6.2,
2.7)
0.493
Ivabradine
1 (0.8%)
3 (2.5%)
-1.7% (-4.9,
1.5)
0.362
MRA
4 (3.2%)
3 (2.5%)
0.7% (-3.5, 4.9)
1.000
Other HF Meds
9 (7.2%)
2 (1.7%)
5.5% (0.5, 10.6)
0.060
* p-value from 2-sided Fisher's exact test
4
Zile et al, Appendix Table 12: Subjects Adding New Class of Heart Failure Drugs by Six Months in Cohort D
Control (N=125), Supplemental Information to "Baroreflex Activation Therapy in Patients With Heart
Failure With Reduced Ejection Fraction." J Am Coll Cardiol 76(1): 1-13, 2020. (Error! Reference
source not found.)